TREATMENT OF HEPATITIS C WITH DIRECT ACTING ANTIVIRAL DRUGS CAN PROTECT AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 INFECTION

Main Article Content

Mohamed Alboraie
Ahmed Cordie
Waleed Ismail
Ahmed Abu-Elfatth
Dina Ziada
Ahmed Gomaa
Mohamed Hussien
Mohamed Abd Allah
Marwa Ibrahim
Eman Adel
Ahmed Fouad Sherief
Hany Sayed
Omar Elshaarawy
Mohamed Ahmed Medhat
Gina Gamal Naguib
Ahmed Saleh
Eman D. El Desouky
Ibrahim Amer
Ola Deghedy
Doaa Saleh
Sherief Abd-Elsalam
Mohamed El Kassas
Yasser Fouad
Mahmoud El-Bendary
Gamal Esmat

Keywords

Treatment, coronavirus, COVID-19

Abstract

Owing to the similarity between SARS-CoV-2 and hepatitis C virus (both SARS-CoV-2 Mpro protease and HCV NS3/4A protease are double B-barrel folded with similar orientation), and based on molecular docking models, many researchers suggested using hepatitis C direct acting antiviral drugs (DAAs) for the treatment of SARS-CoV-2 infection.


Aims & Methods:


This study aimed to estimate the prevalence of SARS-CoV-2 infection among chronic hepatitis C patients receiving treatment with sofosbuvir plus daclatasvir in comparison to chronic hepatitis C patients who finished treatment course one year before COVID-19 pandemic (control group). 500 chronic hepatitis C patients were included in our study who was receiving treatment with sofosbuvir plus daclatasvir (study group) during COVID-19 pandemic (March to September 2020) in comparison to matched 500 individuals who finished treatment course for hepatitis C one year (March to September 2019) before COVID-19 pandemic (control group). Both groups were followed up for 6 months starting from March 2020 up to September 2020. Baseline demographic data, comorbidities, history of confirmed diagnosis of with SARS-CoV-2 infection, or close contact with confirmed or suspected cases were compared in both groups.


Results:


Our study included 1000 participants (500 in each group), mean age ± SD was 48.45 ± 7.68 in the study group and 47.67 ± 10.56in the control group (p value=0.18). Most of participants in the study were males, 400 (80%) in the study group and 380 (76%) in the control group. No significant differences were present in baseline characteristics including area of residence (rural versus urban), level of education, work in medical field, smoking, presence of liver cirrhosis or other comorbidities (Diabetes mellitus, Hypertension, Chest diseases, Cardiac disease, Autoimmune disease or Obesity). In the study group 22 (4.4%) patients had contact with SARS-CoV-2 infected patient while in the control group 24 (4.8%) individuals had contact with SARS-CoV-2 infected patient (p value=0.88). Patient receiving chronic hepatitis C treatment with sofosbuvir plus daclatasvir had a lower rate of SARS-CoV-2 infection (2.2%, 11 SARS-CoV-2 infections) than individuals in the control group (6%, 30 SARS-CoV-2 infections) with p value =0.002.

Abstract 81 | pdf Downloads 64

References

1. Hilgenfeld R and M Peiris. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviralresearch 2013. 100(1): p. 286-295.
2. A.A. Elfiky, S.M. Mahdy, W.M. Elshemey, Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses, J. Med. Virol. 89 (2017) 1040–1047.
3. Bogoch, A. Watts, A. Thomas-Bachli, C. Huber, M.U.G. Kraemer, K. Khan, Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel, Journal of Travel Medicine (2020).
4. D.S. Hui, I.E. Azhar, T.A. Madani, F. Ntoumi, R. Kock, O. Dar, et al., The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China, International Journal of Infectious Diseases 91 (2020) 264–266.
5. Elfiky AA, SM Mahdy and WM Elshemey, Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. Journal of medical virology, 2017. 89(6): p. 1040-1047.
6. Organization WH. 2020. WHO R&D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020. WHO/HEO/R & D Blueprint ( nCoV) 401 /2020.1.
7. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medrxiv 2020. doi:10.1101/2020.03.22.20040758
8. Keating GM. 2014. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs 452 74:1127–1146.
9. A.A. Elfiky, A.M. Ismail, Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor, Futur. Virol. 12 (2017) 339–347.
10. Masoud HH, Elassal G, Zaky S, et al. Management Protocol for COVID-19 Patients. Ministry of health and population (MOHP), Egypt. Version 1.4/30th May 2020 available on line at http://www.mohp.gov.eg/JobsDetails.aspx?job_id=3061
11. Abd-Elsalam S, Esmail ES, Khalaf M, et al. Tanta Protocol for Management of COVID-19: Perspectives from a Developing Country. Endocr Metab Immune Disord Drug Targets. 2020 Nov 17. doi: 10.2174/1871530320999201117142305. Online ahead of print.
12. Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. Am J Trop Med Hyg. 2020 Oct; 103(4):1635-1639.
13. Abd-Elsalam S, Soliman S, Esmail ES, et al. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine? a Randomized, Multicenter Trial. Biol Trace Elem Res. 2020 Nov 27:1-5. doi: 10.1007/s12011-020-02512-1. Online ahead of print.
14. Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. J Antimicrob Chemother. 2020 Nov 1; 75: 3373-3378.
15. Eslami G, Mousaviasl S, Radmanesh E, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020; 75: 3366-3372.
16. Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020; 75: 3379-3385.
17. Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2020 Dec 18; : dkaa501https://doi.org/10.1093/jac/dkaa501
18. Elfiky AbdAllah M, Alboraie M, Abdel-Razek W, et al. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver international: official journal of the International Association for the Study of the Liver. 2021.
19. Elbaz T, Waked I, El-Akel W, et al. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Review of Anti-infective Therapy. 2021: null-null.
20. El-Bendary M, abd-elsalam S, Elbaz T, et al. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Review of Anti-infective Therapy. 2021: null-null.
21. Elalfy H, Besheer T, El‐Mesery A, et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS. NRIZ study) on the clearance of mild COVID‐19. Journal of medical virology. 2021;93(5):3176-3183.